Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy
University of Pittsburgh
University of Pittsburgh
Columbia University
Bristol-Myers Squibb
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb
Nektar Therapeutics
Bristol-Myers Squibb